Gene therapy
News
November 30, 2023
Genethon evaluates a new therapeutic approach for glycogen storage disease III
(read more)
November 21, 2023
NEWSLETTER : “We have multiple examples of how these technologies can be used to develop products that more efficient and safer with improved production technologies”
(read more)
November 17, 2023
Myotubular myopathy: gene therapy trial results demonstrate major improvement of motor and respiratory functions
(read more)
November 17, 2023
Clinical results of the gene therapy trial in myotubular myopathy : efficacy on respiratory and motor functions in this extremely severe disease, challenges ahead
(read more)
October 27, 2023
First clinical results of a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy presented at ESGCT Congress
(read more)
October 24, 2023
The Latest Research of 14 Généthon Scientists to be Featured at the European Society of Gene & Cell Therapy’s 30th Annual Congress, Oct. 24-27, 2023, in Brussels, Belgium
(read more)
September 15, 2023
Genethon assesses a therapeutic potential of a Dual AAV vector approach for Duchenne muscular dystrophy
(read more)
September 11, 2023
Genethon’s Optidys project rewarded by BpiFrance as part of France 2030
(read more)
August 17, 2023
First results of Crigler-Najjar clinical trial published in New England Journal of Medicine
(read more)
July 12, 2023
Genethon and Thales collaborate on artificial intelligence to improve bioproduction efficiency
(read more)
May 30, 2023
Research work carried out at Genethon rewarded at the 26th edition of the ASGCT
(read more)
May 12, 2023
Genethon’s R&D to be Featured in Multiple Presentations at American Society of Gene & Cell Therapy Annual Meeting May 16-20, 2023, in Los Angeles, CA
(read more)
May 12, 2023
ILTOO Pharma and the MIROCALS Consortium announce the signing of Licence Agreement for the development of low dose interleukin-2 as a potential treatment for Amyotrophic Lateral Sclerosis (ALS)
(read more)
April 27, 2023
Crigler-Najjar syndrome: Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy for patients with anti-AAV antibodies
(read more)
March 6, 2023
Crigler-Najjar Syndrome: Genethon obtains PRIME priority drug status from the EMA for its gene therapy
(read more)
February 24, 2023
Chronic septic granulomatosis: biomarkers predict the efficacy of gene therapy
(read more)
February 7, 2023
"We made important achievements in 2022 but we still face key challenges in the year ahead"
(read more)
Serving the public interest
Our mission: Conception, clinic and preclinic development of drugs of genic therapy for rare diseases
Our goal: Providing these innovative treatments to the sick
